Clinical trials: PET-CT, open to volunteers
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
This is an exploratory study to assess [18F]PT2385 Positron Emission Tomography/Computed Tomography (PET/CT) in patients with renal cell carcinoma (RCC). This is an open-label, nontherapeutic trial.
- Trial name
- NCT04989959
- Testing
- [18F]PT2385, Positron Emission Tomography/Computed Tomography, Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Orhan Kemal Oz
Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors
FTT PET/CT in Pancreatic Neuroendocrine Tumors
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, [18F]FluorThanatrace ([18F]FTT).
- Trial name
- NCT07114939
- Testing
- [18F]FluorThanatrace
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Prostate Cancer 18F-PSMA-1007 PET/CT Access Trial
Primary objective: To determine if 18F-PSMA-1007 PET/CT imaging is effective at diagnosing prostate cancers and/or metastases compared to conventional imaging [including CT, MRI, 99mTc-MDP Bone Scans as available].
- Trial name
- PAX (NCT06489496)
- Testing
- 18F-1007 PSMA PSMA PET/CT
- Volunteers
- 1,000 people
- Sponsor
- Alberta Health services
Aortic Valve Stenosis, Coronary Artery Disease
Correlation of FFR and iFR With Cardiac PET Perfusion in Patients With Severe Aortic Valve Stenosis
Aortic valve stenosis (AS) affects 2-7% of persons > 65 years, symptoms include: angina and dyspnea, dizziness and syncope. Coincidence of coronary artery disease (CAD), also presenting with angina and dyspnea, in patients with…
- Trial name
- TAVI PET (NCT04882488)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heart and Diabetes Center North-Rhine Westfalia
Endometriosis
Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions
Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations.
- Trial name
- ENDO-TEP (NCT07053982)
- Testing
- Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse
Neuroendocrine Tumor, Liver Metastases
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options.
- Conditions
- Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour
- Trial name
- LUTARTERIAL (NCT04837885)
- Testing
- Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection
- Where
- 4 sites in France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Bordeaux
Prostate Cancer
PET/CT Characterization of Treatment Resistance
This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that…
- Trial name
- NCT05647564
- Testing
- F-fluorodeoxyglucose positron emission tomography (FDG PET), prostate-specific membrane antigen positron emission tomography (PSMA PET)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Wisconsin, Madison
Solid Tumor (Excluding CNS), HER2
68Ga-XHER2 PET/CT for HER2 Assessment
The objective of this study is to evaluate the feasibility of 68Ga-XHER2 PET/CT as a noninvasive imaging approach for assessing HER2 expression in patients with solid tumors and to investigate the correlation between tracer…
- Conditions
- Solid Tumor (Excluding CNS), HER2, PET / CT
- Trial name
- NCT07885436
- Testing
- 68Ga-XHER2 PET/CT
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Mantle Cell Lymphoma
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
This is a single-arm, multi-center, prospective, phase II study. The primary objective is to assess the efficacy and safety of bendamustine/orelabrutinib combined with an anti-CD20 monoclonal antibody in treatment-naïve patients…
- Trial name
- ADAPT-MCL (NCT07206264)
- Testing
- Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 45 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC)
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC).
- Trial name
- NCT07019844
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- VA Office of Research and Development
Cushing Disease, Pituitary Adenoma
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
The purpose of this research is to evaluate the performance [sensitivity, specificity, accuracy] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
- Trial name
- NCT07460232
- Testing
- Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Uterine Cancer
[18F]FES PET/.CT in Uterine Cancer
Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the…
- Trial name
- NCT05916196
- Testing
- 18F-Fluoroestradiol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma (HCC)
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
This study aims to investigate the value of 68Ga-FAPI PET/CT in the efficacy evaluation of advanced unresectable hepatocellular carcinoma patients undergoing systemic antitumor therapy.
- Trial name
- NCT06746194
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Cushing Syndrome
Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT
The incidence of Cushing syndrome (CS) is 1.2-3.2 cases per million per year, of which adrenocorticotropic Hormone (ACTH)-dependent disease comprises approximately 70-80% of cases.
- Trial name
- Ga-68 mDesmo (NCT06962202)
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Prostate Cancers, Breast Cancer
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings.
- Conditions
- Prostate Cancers, Breast Cancer, Head and Neck Cancer, Cancer
- Trial name
- PETRiS (NCT06970275)
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 850 people
- Sponsor
- XEOS Medical
Prostate Cancer
Radioactive Counts From PSMA PET/CT-Targeted Biopsy Specimens for Real-time Diagnosis of Prostate Cancer: A Prospective Study
This study aims to establish the diagnostic threshold and efficacy of radioactive counts (CPM) from biopsy specimens in distinguishing cancer-containing from non-cancer-containing cores, using prostate biopsy pathology as the…
- Trial name
- NCT07709403
- Testing
- No intervention (observational study)
- Volunteers
- 20 people
- Sponsor
- Peking University First Hospital
Primary Aldosteronism, Autonomous Cortisol Secretion
68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT)
To validate the accuracy of 68Ga-Pentixafor PET/CT and adrenal venous sampling (AVS) in subtype diagnosis of PA/ACS patients with adrenal nodules, based on biochemical and clinical remission outcomes, and to determine whether the…
- Trial name
- NCT06833437
- Testing
- 68Ga-Pentixafor PET/CT, AVS
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Qifu Li
Prostatic Neoplasms, Prostate Cancer
Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study
This study aims to evaluate the diagnostic performance of [68Ga]Ga-OncoACP3 PET imaging, which targets prostate acid phosphatase (ACP3), in men with clinically suspected or confirmed high-risk prostate cancer, or suspected…
- Trial name
- NCT07830212
- Testing
- [68Ga]Ga-OncoACP3
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yong He
Classical Hodgkin Lymphoma, Child
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing.
- Conditions
- Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult
- Trial name
- NCT06563245
- Testing
- Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Children's Cancer Group, China
Small Cell Lung Cancer, Small Cell Lung Carcinoma
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.
- Trial name
- NCT04199741
- Testing
- 89Zr-DFO-SC16.56, SC16.56, Phase I, Cohort 2, SC16.56, Phase I, Cohort 3
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Memorial Sloan Kettering Cancer Center